Vinay Prasad
#39,716
Most Influential Person Now
US hematologist–oncologist
Vinay Prasad's AcademicInfluence.com Rankings
Vinay Prasadmedical Degrees
Medical
#293
World Rank
#431
Historical Rank
#129
USA Rank
Hematology
#11
World Rank
#12
Historical Rank
#6
USA Rank
Oncology
#23
World Rank
#24
Historical Rank
#10
USA Rank
Download Badge
Medical
Why Is Vinay Prasad Influential?
(Suggest an Edit or Addition)According to Wikipedia, Vinayak K. Prasad is an American hematologist-oncologist and health researcher. He is a professor of Epidemiology and Biostatistics at the University of California, San Francisco . He is the author of the books Ending Medical Reversal and Malignant .
Vinay Prasad's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs (2019) (623)
- Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices (2014) (532)
- A decade of reversal: an analysis of 146 contradicted medical practices. (2013) (323)
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017) (289)
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. (2015) (263)
- The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. (2015) (251)
- The high price of anticancer drugs: origins, implications, barriers, solutions (2017) (242)
- Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. (2015) (240)
- Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology (2018) (237)
- Perspective: The precision-oncology illusion (2016) (220)
- Prespecified falsification end points: can they validate true observational associations? (2013) (205)
- Reversals of established medical practices: evidence to abandon ship. (2012) (188)
- Precision oncology: origins, optimism, and potential. (2016) (158)
- Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? (2017) (148)
- Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers (2018) (144)
- The frequency of medical reversal. (2011) (132)
- Evidence of placental abruption as a chronic process: associations with vaginal bleeding early in pregnancy and placental lesions. (2006) (125)
- Development and Maturation of the Pediatric Human Vocal Fold Lamina Propria (2005) (121)
- Diagnosis of placental abruption: relationship between clinical and histopathological findings. (2010) (120)
- Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. (2017) (108)
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. (2019) (107)
- Why cancer screening has never been shown to “save lives”—and what we can do about it (2016) (106)
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs (2020) (98)
- Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. (2017) (85)
- Medical Reversal: Why We Must Raise the Bar Before Adopting New Technologies (2011) (84)
- Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. (2016) (82)
- An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. (2019) (81)
- Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. (2015) (76)
- Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy (2018) (75)
- Examining the Use of Real‐World Evidence in the Regulatory Process (2019) (71)
- A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals (2019) (68)
- Authorship Inflation in Medical Publications (2015) (67)
- Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. (2013) (66)
- Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. (2021) (64)
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. (2019) (62)
- The Use of Superlatives in Cancer Research. (2016) (61)
- Cutaneovisceral Angiomatosis With Thrombocytopenia (2005) (58)
- Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. (2014) (58)
- The accelerated approval of oncologic drugs: lessons from ponatinib. (2014) (54)
- Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. (2019) (54)
- The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? (2013) (54)
- Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing. (2018) (52)
- Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. (2014) (52)
- Media Coverage of Medical Journals: Do the Best Articles Make the News? (2014) (49)
- The influence of maternal cigarette smoking on placental pathology in pregnancies complicated by abruption. (2007) (49)
- The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. (2020) (48)
- Colonic diverticulitis in adolescents: an index case and associated syndromes (2009) (47)
- Chest pain in the emergency department: the case against our current practice of routine noninvasive testing. (2012) (47)
- Visual recovery and predictors of visual prognosis after managing traumatic cataracts in 555 patients (2011) (46)
- Real-world Evidence-What Does It Really Mean? (2019) (45)
- Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy (2015) (44)
- Do cancer drugs improve survival or quality of life? (2017) (44)
- The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. (2012) (42)
- FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019 (2020) (41)
- Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter (2017) (40)
- Does the Declining Lethality of Gunshot Injuries Mask a Rising Epidemic of Gun Violence in the United States? (2014) (39)
- Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. (2020) (38)
- Comparative effectiveness questions in oncology. (2014) (37)
- US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity? (2014) (36)
- Characteristics of Exceptional or Super Responders to Cancer Drugs. (2015) (35)
- The misguided ethics of crossover trials. (2014) (35)
- Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. (2015) (34)
- Distinctive clinical characteristics of malignant mesothelioma in young patients (2015) (34)
- Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials (2020) (34)
- Association between treatment toxicity and outcomes in oncology clinical trials. (2014) (33)
- Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. (2016) (32)
- Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption? (2016) (32)
- Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? (2017) (31)
- The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. (2014) (30)
- The College of American Pathologists Guidelines for Whole Slide Imaging Validation are Feasible for Pediatric Pathology: A Pediatric Pathology Practice Experience (2015) (30)
- Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World (2017) (28)
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study (2018) (26)
- Improving observational studies in the era of big data (2018) (26)
- Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. (2020) (26)
- Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. (2016) (26)
- The Rising Price of Cancer Drugs—A New Old Problem? (2017) (25)
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action (2021) (25)
- Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. (2016) (24)
- A reality check of the accelerated approval of immune-checkpoint inhibitors (2019) (24)
- Industry Funding of Cancer Patient Advocacy Organizations. (2016) (23)
- A medical burden of proof: Towards a new ethic (2012) (23)
- Segmental multicystic dysplastic kidney in children. (2006) (22)
- Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. (2018) (22)
- When is crossover desirable in cancer drug trials and when is it problematic? (2018) (21)
- Drugs that lack single-agent activity: are they worth pursuing in combination? (2017) (20)
- Future jobs of FDA’s haematology-oncology reviewers (2016) (20)
- Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. (2021) (20)
- Conflicts of interest in Twitter. (2017) (20)
- Low-value approvals and high prices might incentivize ineffective drug development (2018) (20)
- Loss of the PTCH1 gene locus in cardiac fibroma. (2008) (20)
- The effect of maternal thrombophilia on placental abruption: Histologic correlates (2009) (19)
- Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. (2018) (19)
- Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. (2011) (19)
- Are We Treating Professionalism Professionally? Medical School Behavior as Predictors of Future Outcomes (2011) (19)
- A pooled analysis of published, basket trials in cancer medicine. (2018) (18)
- Reclaiming the morbidity and mortality conference: between Codman and Kundera (2010) (18)
- Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? (2020) (17)
- The role of censoring on progression free survival: oncologist discretion advised. (2015) (17)
- Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. (2020) (16)
- How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. (2015) (16)
- The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. (2016) (16)
- Non-inferiority trials: why oncologists must remain wary. (2015) (16)
- Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. (2016) (16)
- The Case for Being a Medical Conservative. (2019) (16)
- What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. (2017) (15)
- A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. (2018) (15)
- The evidence landscape in precision medicine (2020) (15)
- Considering benefit and risk before routinely recommending SpaceOAR. (2021) (15)
- Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. (2017) (15)
- Xanthogranulomatous Appendicitis in a Child: Report of a Case and Review of the Literature (2013) (15)
- Precision medicine in acute myeloid leukemia: Hope, hype or both? (2016) (15)
- Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm (2021) (14)
- Double-crossed: why crossover in clinical trials may be distorting medical science. (2013) (14)
- Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non–Small Cell Lung Cancers (2020) (14)
- Utility of Screening for Chronic Granulomatous Disease in Patients with Inflammatory Bowel Disease (2012) (14)
- Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? (2014) (14)
- Health policy: Me-too drugs with limited benefits — the tale of regorafenib for HCC (2017) (14)
- Publication trends among internal medicine residents and graduates. (2012) (13)
- Combining drugs and extending treatment — a PFS end point is not sufficient (2017) (13)
- Me too-drugs with limited benefits — the tale of regorafenib for HCC (2017) (13)
- The Peltzman effect and compensatory markers in medicine. (2014) (13)
- The cardiovascular biomarker conundrum: challenges and solutions. (2011) (13)
- The US Food and Drug Administration’s use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation (2018) (13)
- Cardiovascular primary prevention: how high should we set the bar? (2012) (13)
- Use of the Word “Cure” in the Oncology Literature (2015) (13)
- Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib (2019) (12)
- Can a Resident's Publication Record Predict Fellowship Publications? (2014) (12)
- Our best weapons against cancer are not magic bullets (2020) (12)
- Placental mesenchymal dysplasia: a potential misdiagnosed entity (2009) (12)
- Persistent Challenges with Treating Multiple Myeloma Early. (2020) (12)
- Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis. (2018) (12)
- Do we need randomised trials for rare cancers? (2015) (11)
- Solid pseudopapillary neoplasm of the pancreas in pediatric patients: A case report and institutional case series (2015) (11)
- Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings (2017) (11)
- Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing. (2021) (11)
- Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? (2015) (11)
- Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine (2015) (11)
- Pathologic aneurysmal dilation of the ascending aorta and dilation of the main pulmonary artery in patients with Kabuki syndrome: valve-sparing aortic root replacement. (2007) (11)
- Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials (2021) (11)
- Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. (2013) (11)
- The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. (2018) (11)
- Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. (2011) (10)
- Clostridium difficile diarrhea and fecal transplantation. (2011) (10)
- Medical Debates and Medical Reversal (2015) (10)
- Perspective: beyond storytelling in medicine: an encounter-based curriculum. (2010) (10)
- Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. (2017) (10)
- Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. (2020) (10)
- Open issues with open access publication. (2013) (10)
- The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. (2022) (10)
- Multiplying therapies and reducing toxicity in metastatic melanoma (2015) (10)
- Case Reports in the Age of Twitter. (2019) (10)
- Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (2018) (10)
- The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval. (2021) (10)
- Handheld ultrasounds: pocket sized, but pocket ready? (2013) (9)
- Confirmatory Trials for Drugs Approved on a Single Trial. (2019) (9)
- Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? (2020) (9)
- Duty Hour Reform in a Shifting Medical Landscape (2013) (9)
- Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. (2018) (9)
- Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. (2018) (9)
- Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020 (2021) (9)
- Choice of control group in randomised trials of cancer medicine: are we testing trivialities? (2018) (9)
- Evaluating health system processes with randomized controlled trials. (2013) (8)
- Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021 (2022) (8)
- Negative trials in ovarian cancer: is there such a thing as too much optimism? (2016) (8)
- Translation failure and medical reversal: Two sides to the same coin. (2016) (8)
- Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020 (2021) (8)
- Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma (2019) (8)
- The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review (2022) (8)
- Multiplicity in oncology randomised controlled trials: a threat to medical evidence? (2019) (8)
- A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda (2019) (8)
- Characteristics of cluster randomized trials: are they living up to the randomized trial? (2013) (8)
- Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration (2018) (8)
- Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform (2020) (8)
- The reversal of cardiology practices: interventions that were tried in vain. (2013) (8)
- Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. (2020) (8)
- Powering cancer screening for overall mortality (2013) (7)
- Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs? (2019) (7)
- But how many people died? Health outcomes in perspective (2015) (7)
- Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? (2018) (7)
- Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? (2021) (7)
- The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt (2021) (7)
- Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? (2016) (7)
- Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies (2016) (7)
- Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. (2020) (7)
- Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission (2018) (7)
- Overestimating the Benefit of Cancer Drugs. (2017) (7)
- Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. (2021) (6)
- Statins, Primary Prevention, and Overall Mortality (2014) (6)
- Limitations Concerning the Association of Physician Sex and Patient Outcomes. (2017) (6)
- How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. (2021) (6)
- Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were (2018) (6)
- Tebentafusp in first-line melanoma trials: An outperforming outlier (2022) (6)
- Assessing Pharmaceutical Research and Development Costs-Reply. (2018) (6)
- Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? (2016) (6)
- Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer (2021) (6)
- Counterpoint: were industry-sponsored roflumilast trials appropriate? No. (2014) (6)
- Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it. (2018) (6)
- Same Data; Different Interpretations (2016) (6)
- Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? (2020) (6)
- Trends in drug revenue among major pharmaceutical companies: A 2010‐2019 cohort study (2021) (6)
- Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. (2020) (6)
- Modern drug development: which patients should come first? (2014) (6)
- Effect of Clinical Vignettes on Senior Medical Students' Opinions of Climate Change (2011) (6)
- The Necessity of Sham Controls. (2019) (6)
- Persistent reservations against the premedical and medical curriculum (2013) (5)
- Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither? (2019) (5)
- Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more (2013) (5)
- Constructive and obsessive criticism in science (2022) (5)
- Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers? (2018) (5)
- The overdiagnosis of pneumonia (2013) (5)
- Overall Survival vs Disease-Specific Survival-Reply. (2017) (5)
- Dense breasts and legislating medicine (2013) (5)
- Inconsistent Reporting of Potential Conflicts of Interest. (2018) (5)
- Synovial Chondromatosis of the Cervical Spine: A Case Report and Review of the Literature (2014) (5)
- High US drug prices have global implications (2022) (5)
- Toward a Meaningful Alternative Medicine (2009) (5)
- Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals (2017) (5)
- Infantile Osteopetrosis and Juvenile Xanthogranuloma Presenting Together in a Newborn: A Case Report and Literature Review (2011) (5)
- When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor. (2020) (5)
- Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19 (2020) (5)
- Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration (2019) (5)
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (2020) (5)
- Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. (2021) (5)
- The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. (2021) (5)
- Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology (2022) (5)
- Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. (2021) (5)
- FDA decisions on new oncological drugs. (2022) (5)
- Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. (2021) (5)
- The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another. (2019) (5)
- Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis (2020) (5)
- Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. (2020) (4)
- Characteristics of oncology podcasts: Attitudes, speakers, conflicts. (2022) (4)
- Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? (2015) (4)
- The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. (2020) (4)
- COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities (2022) (4)
- A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. (2020) (4)
- Multi-cancer screening tests: communicating about risks should be prioritized. (2021) (4)
- The response rate of alternative treatments for drugs approved on the basis of response rate (2020) (4)
- Rosai-Dorfman disease of the tonsil in a 4-year-old boy: Case report and review of the literature (2011) (4)
- Reversal of warfarin era thinking (2018) (4)
- Falsification end points for observational studies--reply. (2013) (4)
- Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals (2019) (4)
- Treatment of Moderate to Severe Hidradenitis Suppurativa (2013) (4)
- Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? (2021) (4)
- Reversals of Established Medical Practices (2016) (4)
- Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. (2019) (4)
- An unmeasured harm of screening. (2012) (4)
- Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. (2019) (4)
- Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms? (2021) (4)
- Clinically meaningful benefit: real world use compared against the American and European guidelines (2017) (4)
- MOLECULAR DOCKING STUDIES OF MAGE INHIBITORS IN THE TREATMENT OF LUNG CANCER (2013) (4)
- Targeted therapy in lung cancer: Are we closing the gap in years of life lost? (2022) (4)
- Utility of Tissue Transglutaminase Immunohistochemistry in Pediatric Duodenal Biopsies: Patterns of Expression and Role in Celiac Disease—A Clinicopathologic Review (2013) (4)
- Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. (2015) (4)
- Where are randomized trials necessary: Are smoking and parachutes good counterexamples? (2021) (4)
- A rare presentation of a common entity: Chronic appendicitis in a patient with back pain (2017) (4)
- Histopathologic identification and pattern recognition of common viral infections in the general pathology practice: An illustrated review (2016) (4)
- Cancer screening: A modest proposal for prevention (2019) (3)
- Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. (2021) (3)
- Crossover is not associated with faster trial accrual. (2017) (3)
- Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. (2017) (3)
- The apples and oranges of cost-effectiveness (2012) (3)
- Making adjuvant therapy decisions with uncertain data (2019) (3)
- Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing. (2017) (3)
- Should Evidence Come with an Expiration Date? (2019) (3)
- Pembrolizumab as first‐line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is? (2017) (3)
- Approval and Coverage of Cancer Drugs in England, Canada, and the US. (2021) (3)
- The Declining Demand for Hospital Care as a Rationale for Duty Hour Reform (2014) (3)
- Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That? (2018) (3)
- Retrospective comparative effectiveness research: Will changing the analytical methods change the results? (2022) (3)
- Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. (2019) (3)
- Use of word “unprecedented” in the media coverage of cancer drugs: Do “unprecedented” drugs live up to the hype? (2017) (3)
- Primary care physicians' role in counseling about gun safety. (2014) (3)
- Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? (2022) (3)
- Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply. (2018) (3)
- Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. (2022) (3)
- Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. (2021) (3)
- Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials (2022) (3)
- Idecabtagene vicleucel: questions regarding the appropriate role and cost (2021) (3)
- The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword? (2021) (3)
- Eliminating chronic kidney disease… as a diagnosis. (2014) (3)
- Temporal trends in oncology drug revenue among the world’s major pharmaceutical companies: A 2010-2019 cohort study. (2021) (3)
- Fatal extraintestinal adrenal malignancy in a 12-year-old girl with familial adenomatous polyposis. (2014) (3)
- News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. (2020) (3)
- In reply I-reversal of medical practices. (2013) (3)
- Rosiglitazone, medical reversal, and back to basics for diabetes. (2014) (3)
- The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? (2016) (3)
- When research evidence is misleading. (2013) (3)
- Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. (2016) (3)
- FDA acceptance of surrogate endpoints in later lines of therapy. (2018) (3)
- The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018 (2021) (3)
- Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. (2020) (3)
- Pediatric Xanthogranulomatous Cystitis (2017) (3)
- Overall survival for oncology drugs approved for genomic indications (2021) (2)
- FDA Validation of Surrogate Endpoints in Oncology: 2005-2022. (2022) (2)
- Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors (2021) (2)
- US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation (2020) (2)
- The inferior vena cava filter--reply. (2013) (2)
- Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? (2014) (2)
- Is "Do Everything!" Always Appropriate?-Reply. (2017) (2)
- Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer (2021) (2)
- Contact Tracing Policy for Masked Students May be an Important Confounding Variable. (2022) (2)
- How Often Do Highly Promising Cancer Biology Discoveries Translate into Effective Treatments? (2020) (2)
- Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? (2019) (2)
- A Strategy for Helicobacter Immunohistochemistry Utilization in Pediatric Practice: Insights From Morphologic and Cost-Benefit Analyses. (2016) (2)
- Registration studies — when should patients be deemed ineligible for aggressive therapy? (2019) (2)
- Why is research in early-stage cancer research so low? (2018) (2)
- Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). (2020) (2)
- Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. (2021) (2)
- Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? (2020) (2)
- Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022 (2022) (2)
- It is time to stop screening for prostate cancer. (2014) (2)
- The reply. (2014) (2)
- Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. (2019) (2)
- Intestinal Predictors of Whole Blood Serotonin Levels in Children With or Without Autism (2022) (2)
- Quality of biomarker defined subgroups in FDA approvals of PD‐1/PD‐L1 inhibitors 2014 to 2020 (2022) (2)
- Estimation of US patients with cancer who may respond to cytotoxic chemotherapy (2020) (2)
- Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? (2016) (2)
- Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines (2022) (2)
- Assessment of New Molecular Entities Approved for Cancer Treatment in 2020 (2021) (2)
- Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020 (2022) (2)
- A further strategy to combat the high price of anticancer drugs (2017) (2)
- Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm? (2022) (2)
- Eosinophilic esophagitis: A brief review (2015) (2)
- Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap? (2020) (2)
- Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination (2021) (2)
- Unanticipated Outcomes: A Medical Memoir-A Book Review. (2018) (2)
- Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials (2022) (2)
- The accelerated approval pathway in oncology: Balancing the benefits and potential harms. (2022) (2)
- Caution needed when predicting problem residents. (2011) (2)
- Extrarenal Wilms Tumor With Skeletal and Glial Differentiation (2018) (2)
- Evolocumab in Patients with Cardiovascular Disease. (2017) (2)
- Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. (2015) (2)
- Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method (2019) (2)
- Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies (2021) (2)
- Shameful (2014) (2)
- Statistical significance and clinical evidence - Authors' reply. (2020) (1)
- Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public. (2016) (1)
- The US Food and Drug Administration’s use of pathologic complete response as regulatory endpoint: Did it pay off? (2018) (1)
- Medical Reversals in Family Practice: A Review (2020) (1)
- Precision medicine in diffuse large B-cell lymphoma: Hype or hope? (2016) (1)
- Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply. (2018) (1)
- Medical reversals in low- and middle-income countries. (2019) (1)
- The need to assess financial adverse events. (2018) (1)
- Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. (2014) (1)
- Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses (2015) (1)
- Regarding empiricism and rationalism in medicine and 2 medical worldviews. (2014) (1)
- A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment (2019) (1)
- Why Is Research in Early-Stage Cancer Research so Low? A Re-Assessment of Budish, Roin and Williams (2015) (2017) (1)
- Addendum: Low-value approvals and high prices might incentivize ineffective drug development (2018) (1)
- How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost. (2016) (1)
- PFO closure for secondary stroke prevention: is the discussion closed? (2018) (1)
- The Reply. (2019) (1)
- Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. (2010) (1)
- Statistical significance of bevacizumab trials when considering the portfolio of all studies. (2018) (1)
- Emphasizing unique strengths and eliminating redundancy for research in low‐income and middle‐income countries: Lessons from a South American country (2015) (1)
- Unanticipated Outcomes: A Medical Memoir-A Book Review. (2017) (1)
- Association of financial conflicts of interest with academic success among junior faculty in hematology and oncology. (2020) (1)
- In Vitro Versus In Vivo Culture Sensitivities: An Unchecked Assumption? (2013) (1)
- Observational studies cannot justify the inferior vena cava filter. (2014) (1)
- ASCO Plenary Sessions: impact, legacy, future. (2016) (1)
- Language in the End (2010) (1)
- Exemestane with ovarian suppression in premenopausal breast cancer. (2014) (1)
- The relationship between response and dose in published, contemporary phase 1 oncology trials. (2019) (1)
- Subclavian vein aneurysm secondary to a benign vessel wall hamartoma (2013) (1)
- Pediatric Xanthogranulomatous Cystitis: The First Described Case in a Pre-Pubertal Male and Review of the Literature. (2016) (1)
- Diagnosis of Placental Abruption: Relationship Between Clinical and Histopathological Findings (2010) (1)
- Modern Soft Tissue Pathology: RHABDOMYOMAS AND RHABDOMYOSARCOMAS (2010) (1)
- Spontaneous Cystic Penile Vascular Malformation in an Adolescent and Review of the Literature. (2016) (1)
- Case report of a skip segment Hirschsprung’s disease: A real phenomenon (2021) (1)
- How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature (2022) (1)
- Multiplicity: When many analytic plans are applied or many redundant studies are run, false‐positive results are ensured (2022) (1)
- The regulatory saga of fedratinib (2021) (1)
- Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma (2021) (1)
- Accurate accounting of caplacizumab cost effectiveness. (2021) (1)
- Is it time to reconsider molecular response milestones in chronic myeloid leukemia? (2023) (1)
- Omission of Critical Information From Clinical Trial Reports-What to Do About Uninterpretable Results. (2023) (1)
- Umbrella review of basket and umbrella trials in oncology (2022) (1)
- New drugs and options can enhance patient outcomes: But can they also erode them? (2021) (1)
- Accelerated approval requirements for lurbinectedin. (2022) (1)
- Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020. (2021) (1)
- Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply. (2022) (1)
- Corrigendum to 'Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized' AmJMed 2021;135(4):413-415. (2022) (1)
- The frequency of assessment of progression in randomized oncology clinical trials (2021) (1)
- CostPlus and implications for generic imatinib (2022) (1)
- Drug repurposing in oncology - Authors' reply. (2020) (1)
- Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF (2021) (1)
- Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. (2022) (1)
- An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals (2021) (1)
- Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. (2022) (1)
- The definition of long COVID used in interventional studies. (2023) (1)
- INTRAVITREAL DEXAMETHASONE IMPLANT FOR MANAGEMENT OF SYMPATHETIC OPHTHALMIA – CASE REPORT (2018) (0)
- The effect of cigarette smoking on placental abruption histology: The new jersey-placental abruption study (2006) (0)
- CLINICAL SERIES OF UNUSUAL PRESENTION OF VITELLOINTESTINAL DUCT. (2018) (0)
- Why resident physicians stay late (2013) (0)
- The Search for Another Piece of the Puzzle: A Review of Gastrointestinal Biopsies in 30 Children With Autistic Spectrum Disorder (2012) (0)
- How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. (2017) (0)
- The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial. (2023) (0)
- AJM onlineLetterThe Reply (2013) (0)
- Improving the design of pivotal clinical trials. (2019) (0)
- Tu1825 MEDIA COVERAGE OF THE AMERICAN CANCER SOCIETY'S UPDATE TO COLORECTAL CANCER SCREENING GUIDELINES (2020) (0)
- When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100 (2021) (0)
- A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer (2022) (0)
- Situation Awareness, Cognitive Debriefing, and Strategies Toward Reducing Diagnostic Errors: Teaching Residents to Slow Down (2012) (0)
- The reply. (2013) (0)
- The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. (2022) (0)
- Raise the bar even higher for primary prevention interventions-reply. (2012) (0)
- Disease Specific Productivity of American Cancer Hospitals (2015) (0)
- Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply. (2016) (0)
- Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment (2022) (0)
- Reply to Dr. Leon: true but unrelated. (2016) (0)
- Further thoughts on why there are good data supporting the inferior vena cava filter. (2014) (0)
- General payments from Biogen to U.S. physicians between 2015 and 2020 (2022) (0)
- Inconsistent Reporting of Potential Conflicts of Interest. (2018) (0)
- Design, power, and alpha levels in randomized phase II oncology trials (2023) (0)
- Multiple Comparisons in Variation of Care Research (2017) (0)
- P-135: Time to event surrogate endpoints in multiple myeloma randomized trials from 2005-2019: a systematic review and surrogacy analysis (2022) (0)
- The reply. (2014) (0)
- Eventual success rate and predictors of success for oncology drugs tested in phase I trials (2022) (0)
- CME: Is it Meeting the Mark? (2023) (0)
- Freedom to innovate: the perils of centralized medical research-reply. (2012) (0)
- Routine noninvasive testing and highly sensitive troponin immunoassays--reply. (2013) (0)
- An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC) (2022) (0)
- Are Doctors Selling Derivatives (2013) (0)
- Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. (2015) (0)
- Old-fashioned Intelligence Will Always Be Needed in Medicine. (2021) (0)
- Pricing and Value of Cancer Drugs--Reply. (2015) (0)
- An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough? (2020) (0)
- Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply. (2018) (0)
- Couple therapy for posttraumatic stress disorder. (2012) (0)
- Adjuvant checkpoint inhibitor trials: Is disease-free survival appropriate endpoint? (2023) (0)
- Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals (2017) (0)
- COVID‐19 vaccine induced myocarditis in young males: A systematic review (2022) (0)
- Rebuttal from Dr Rho et al. (2014) (0)
- Data for: Why is Research in Early-Stage Cancer Research so Low? (2018) (0)
- The conundrum of cost-effectiveness. (2012) (0)
- Pembrolizumab for all (2022) (0)
- Recommendation Reversals in Gastroenterology Clinical Practice Guidelines (2021) (0)
- Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals (2023) (0)
- N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA. (2021) (0)
- The Cardiovascular Biomarker Conundrum (2017) (0)
- If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis (2018) (0)
- Concerning survival signal for eltrombopag in MDS/AML (2019) (0)
- What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020) (2022) (0)
- Core limitations in clinical trials leading to anticancer drug approvals by the U.S. Food and Drug Administration. (2020) (0)
- Inconsistent Reporting of Potential Conflicts of Interest. (2018) (0)
- Inconsistent Reporting of Potential Conflicts of Interest. (2018) (0)
- Exercise, Cardiac Rehabilitation, and Post-Acute Coronary Syndrome Depression (2017) (0)
- An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence-Based? (2021) (0)
- In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research? (2016) (0)
- PAXLOVID™: A Regulatory Gamble (2023) (0)
- A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. (2023) (0)
- Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn’t? (2014) (0)
- To 'First, Do No Harm,' You Must Start With Good Evidence. (2016) (0)
- Clinically meaningful benefit: real world use compared against the American and European guidelines (2017) (0)
- Characteristics of Facebook’s third-party medical fact checkers (2022) (0)
- Author response: A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals (2019) (0)
- Interpreting the results from the first randomised controlled trial of colonoscopy: does it save lives? (2023) (0)
- Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma (2023) (0)
- Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (2018) (0)
- The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. (2021) (0)
- Front‐line chronic lymphocytic leukemia: The role of chemoimmunotherapy (2023) (0)
- The apples and oranges of cost-effectiveness: A rejoinder (2012) (0)
- Multiple myeloma triplet therapies: baseline characteristics and control groups (2021) (0)
- Artificial intelligence and magnetic resonance imaging may not make cancer screening better. (2021) (0)
- Ivosidenib and Azacitidine in IDH1-Mutated AML. (2022) (0)
- Medical Science Double-Crossed: Why Crossover in Clinical Trials May Be Distorting (2013) (0)
- The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. (2023) (0)
- Modified Fecal Transplantation (2011) (0)
- Heparin-induced thrombocytopenia: a tremendous opportunity for randomization (2017) (0)
- Firearm legislation and gun-related fatalities. (2013) (0)
- A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. (2021) (0)
- Targeted Cancer Therapies. (2021) (0)
- Taking care of sick patients (2013) (0)
- Comment on "Eliminating chronic kidney disease... as a diagnosis". Authors' reply. (2014) (0)
- Comparability of Control and Comparison Groups in Studies Assessing Long COVID (2023) (0)
- After COVID‐19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems (2021) (0)
- The Reply. (2020) (0)
- Visualizing the randomized sham-controlled trial in orthopedic research: proposed steps to conducting a total knee arthroplasty randomized controlled trial. (2023) (0)
- Persistent reservations against the premedical and medical curriculum (2013) (0)
- MortalityandTreatmentPatternsAmongPatients HospitalizedWithAcuteCardiovascularConditions DuringDatesofNationalCardiologyMeetings (2014) (0)
- Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers (2023) (0)
- Use of Retrospective Data for Comparative Effectiveness Research Yields Mixed Outcomes and Should be Avoided. (2021) (0)
- Reply to C.J. Sweeney et al. (2019) (0)
- Is Financial Toxicity Captured in Assessments of Quality of Life In Oncology Randomized Clinical Trials? (2023) (0)
- JOURNAL DISCUSSION When Research Evidence is Misleading (2013) (0)
- Common misconceptions of randomized controlled trials in oncology (2022) (0)
- The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018 (2021) (0)
- Proportion of Patients with FLT3 Positive AML Required to Enroll on Clinical Trials to Satisfy the Recruitment Needs of FLT3 Inhibitor Trials: Are We Running out of Patients? (2018) (0)
- Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” (2020) (0)
- Estimation of U.S. patients with cancer who may respond to cytotoxic chemotherapy. (2019) (0)
- Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? (2021) (0)
- Roflumilast in COPD: Response (2015) (0)
- Post-protocol therapy and informative censoring in the CANDOR study. (2022) (0)
- Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? (2022) (0)
- An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC) (2022) (0)
- FDA precedents in drug approvals: Contradiction in promoting more treatment options. (2022) (0)
- Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. (2022) (0)
- Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. (2022) (0)
- Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials (2022) (0)
- Submucosal Nerve Diameter in the Rectum Increases With Age: An Important Consideration for the Diagnosis of Hirschsprung Disease (2021) (0)
- Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. (2022) (0)
- Steroids in infection: an old wives’ tale (2011) (0)
- Ciliary Biopsy Quality Improvement: Before and After Establishment of a Primary Ciliary Dyskinesia (PCD) Clinical Center (2019) (0)
- The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. (2021) (0)
- Tu1894 Small Intestinal Polyp Development in 10q23 Deletion Syndrome (2014) (0)
- Front-line CLL: the role of chemoimmunotherapy. (2023) (0)
- Acute histologic inflammatory activity and postoperative outcomes in pediatric patients with ulcerative colitis. (2020) (0)
- Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter. (2023) (0)
- Cecitis With Proctitis: Unusual Pretreatment Presentation of Ulcerative Colitis in Childhood, Potential Diagnostic Pitfalls in an Atypical Presentation (2014) (0)
- A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials (2021) (0)
- The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. (2022) (0)
- Pediatric Dermatology Photoquiz: An Enlarging Facial Papule (2016) (0)
- Improvement of Pediatric Liver Core Biopsy Adequacy by Reducing Laboratory-Related Tissue Fragmentation and Increasing Portal Tract Yield. (2020) (0)
- Utility of Screening for Chronic Granulomatous Disease in Patients with Inflammatory Bowel Disease (2011) (0)
This paper list is powered by the following services:
Other Resources About Vinay Prasad
What Schools Are Affiliated With Vinay Prasad?
Vinay Prasad is affiliated with the following schools:
